Investors
BioSyent is a publicly traded specialty pharmaceutical company. Our issued and outstanding common shares are listed for trading on the TSX Venture Exchange under the symbol “RX”, and OTC markets (PINK) under the ticker “BIOYF.”
BioSyent named to 2024
TSX Venture Top 50
Why Invest?
Track Record of Profitable Growth
54 Consecutive Profitable Quarters to Q4 2023
Strong Balance Sheet
$28.7 million Cash / $0 Debt at Dec 31, 2023
Well Capitalized
18% Reduction in Share Count from Share Buybacks to December 2023
Quarterly Dividend
Initiated Q4 2022
Experienced and Committed Management Team
>10 years average tenure
~25% management + director ownership
Diversified Portfolio of Innovative Products to Drive
Long-term Growth
10 Approved Products
Scalable Commercial Platform
National Field Salesforce
Market Leading FeraMAX® Pd Platform
#1 Recommended Iron Supplement in Canada for
8 Consecutive Years
Q4 Results Presentation 2023
Check out our previous quarterly webcasts on our YouTube channel.
BioSyent’s Strategy
BioSyent’s strategic focus is on commercializing innovative products with recognizable brand equity sourced through international partnerships.
These products are unique due to manufacturing complexities, novel technologies, therapeutic advantages and, defendable intellectual property rights. The Company works with and supports healthcare practitioners in improving patient lives.
BioSyent’s strategy has three components:
- Growth (Revenue and Profit)
- Diversification
- Corporate Longevity
These three strategic components are prioritized in any investment and capital allocation decisions made by the Company, including any decision to return capital to shareholders.
2022 Annual Report
We made significant investments in growth in 2022 – growth for the current year and, more importantly, growth over the long-term. Our Canadian pharmaceutical brands delivered growth in 2022 as we expanded our field salesforce and made significant marketing investments in our established brands, such as FeraMAX®, as well as our launch brands, Tibella® and Combogesic®.
